Finding new ways to deliver care,
from the lab to the clinic to your home.
Demonstrated their lead CAR T cell therapy candidate robustly cured solid tumors in mice with an order of magnitude better efficacy than others - an enormous challenge for cell therapies to date.
Demonstrated Gene Writing efficiency high enough to treat PKU in primates, and in vivo creation of CAR-T cells in mice, opening a door to same-day CAR-T therapy for cancer patients.
Enabled true de novo protein sequencing for the first time with their nanopore technology.
Unveiled pre-clinical data on the efficacy of their “universal” gene therapy for solid tumors, combing AAV gene therapy and cytokine immunotherapy.
Received FDA fast-track designation for their HIV treatment which removes latent virus from patients’ genomes, and released positive interim safety data from their Phase I trial.
Launched the first-ever novel neuroplastogen clinical trial, where interim Phase I results showed their lead asset DLX-001 is well-tolerated and has no psychedelic effects.
Advanced their CRISPR-engineered bacteriophage therapy for UTI through phase 2/3 trials, preserving microbiome health by precisely killing E. Coli cells to tackle antibiotic resistance through precision biotherapeutics.
Announced the commencement of their first-in-class Phase 1 studies for their cancer-fighting TCR-NK cell therapy in patients.
Completed clinical trials for its probiotic solutions for women’s health, IBS and antibiotic recovery.
Initiated a clinical study for a lung cancer detection blood test leveraging their multiomic platform, aiming to improve early detection rates and reduce unnecessary radiation.
Increased patient engagement in lung cancer therapy trials, with 2x more patients sharing their EMR data.
Received FDA approval for their new CORE 500 stethoscope, bringing advanced technology to clinicians worldwide.
Successfully treated 18 patients with their best-in-class targeted radiation system at the world’s first BNCT center at Xiamen Humanity Hospital, and showed evidence of tumor control in head & neck cancer patients
Launched Omni Reporting, generating clinical interest for the next-generation technology that saves radiologists time with generative AI.
Expanded ActivSight, their tissue perfusion mapping technology, to surgeons across 8 systems at 5 hospitals.
Delivered virtual care to more than 5,000 patients struggling with substance use disorder, reporting retention and engagement outcomes twice those of traditional treatment programs.
Launched the next generation of the revamped Sleepbuds to help people fall asleep and stay asleep.
Finalized its ePrescription launch, bringing medication from the pharmacy to your doorstep in under 30 minutes.
Helped over 1 million users navigate grocery stores and restaurants to find food that matches their dietary needs.
Treated more than 750,000 patients to date across all 50 states and leveraged machine learning to create and scale their virtual suicide risk detection system.
